Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ospedale San Raffaele
The study is carried out to evaluate primarily the difference in the activity of the renal transporter ENaC (through dosage of sodium) through its inhibition with a single dose of Amiloride in hypertensive patients characterized by the polymorphism of alpha Adducin rs496. It's also aimed to see the difference in potassium and the change in systolic and diastolic blood pressure after amiloride administration
Age
18–60
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
male patients aged 18-60 years;
naïve hypertensive patients: newly diagnosed, never previously treated for hypertension;
BMI\<30 Kg/m2,
documented first degree essential arterial hypertension (mean of the last 3 consecutive systolic BP measurements must be \>=140 mmHg or diastolic BP \>=90 mmHg;
signature of the informed consent for participation in the study
patient who has already undergone genomic DNA sampling (accompanied by relative consent) and genotyped for the ADD1 rs4961 variant (GG, GT or TT).
You may not be if
known causes of secondary hypertension;
severe or malignant hypertension; history of renal artery disease;
significant renal disease (creatinine clearance less than 60 ml/min);
hyperkalemia (Kpl \> 6mEq/l) at enrollment visit;
hypercalcaemia (Ca pl \> 2.6 mmol/l) at enrollment visit;
symptomatic hyperuricemia (\> 7.5 mg/dl);
liver disease (transaminases greater than 3 times the normal value);
